Tag: Patients
UCB Completes the Acquisition of Ra Pharmaceuticals – to Deliver Differentiated Therapies to Patients

UCB Completes the Acquisition of Ra Pharmaceuticals – to Deliver Differentiated Therapies to Patients

- The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor of ...

Lees verder
ImmuneMed's 'hzVSF,' Used for Treatment of COVID-19 Pneumonia Patients

ImmuneMed's 'hzVSF,' Used for Treatment of COVID-19 Pneumonia Patients

- 'Approved' for treatment purpose usage at Yonsei University Hospital after Seoul National University Hospital, Yeungnam University Hospital and Chungnam National University ...

Lees verder
Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with

Roivant Announces Development of Anti-GM-CSF Monoclonal Antibody to Prevent and Treat Acute Respiratory Distress Syndrome (ARDS) in Patients with

- Gimsilumab is a monoclonal antibody that targets GM-CSF, a pro-inflammatory cytokine found to be up-regulated in COVID-19 patients - Emerging clinical evidence in COVID-19 ...

Lees verder
New Data Confirms Cardiac Dimensions' Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation

New Data Confirms Cardiac Dimensions' Carillon® System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation

Pooled Analysis of Prospective Studies Presented during Late Breaking Trials Session at CRT 2020 KIRKLAND, Washington, Feb. 25, 2020 /PRNewswire/ -- Cardiac Dimensions, a ...

Lees verder
Kowa Achieves Goal Of Randomizing 10,000 Patients Into Landmark "PROMINENT" Cardiovascular Outcomes Study Of K-877 (Pemafibrate)

Kowa Achieves Goal Of Randomizing 10,000 Patients Into Landmark "PROMINENT" Cardiovascular Outcomes Study Of K-877 (Pemafibrate)

Trial will evaluate if lowering triglycerides and increasing functional HDL with Kowa's potent, selective peroxisome proliferator activator receptor-alpha (PPAR-alpha) ...

Lees verder
LPG SYSTEMS Unveils a Major Advancement: Irradiated Mastectomy Patients Can Benefit From Minimally Invasive Breast Reconstruction

LPG SYSTEMS Unveils a Major Advancement: Irradiated Mastectomy Patients Can Benefit From Minimally Invasive Breast Reconstruction

NICE, France, Dec. 9, 2019 /PRNewswire/ -- A pilot study published in the Breast Journal shows the benefits of using Endermologie - a trademark of LPG SYSTEMS - in breast ...

Lees verder
OxThera Presents Full 24-month Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients With ESRD at Kidney Week 2019

OxThera Presents Full 24-month Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients With ESRD at Kidney Week 2019

WASHINGTON, Nov. 7, 2019 /PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), ...

Lees verder
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using

European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using

SAN DIEGO, Oct. 30, 2019 /PRNewswire/ -- Invivoscribe, Inc. announced today that the European Commission (EC) has approved the Astellas drug XOSPATA((TM)) (gilteritinib) as a ...

Lees verder
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcino

European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcino

Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with ...

Lees verder
European Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA®▼ (edoxaba

European Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA®▼ (edoxaba

- One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV ...

Lees verder
BizPress.nl